Home › Preeclampsia › NCT07565727
Cardiometabolic Disease and Substrate Metabolism
RecruitingObservational study
Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study
Who can join
Ages 18 to 45 · Women
Full eligibility criteria
Inclusion Criteria: * Age 18-45 * Any pre-pregnancy BMI * At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines * Willingness to adhere to aspirin therapy * Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc. * Gestational age at enrollment \<18 weeks * Ability to speak, read, and communicate via English Exclusion Criteria: * Type 2 Diabetes Mellitus * Type 1 Diabetes Mellitus * Current gestational diabetes mellitus * Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.) * Thrombophilia * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.) * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.) * Current or recent use of steroids * Current use of prophylactic or therapeutic anticoagulation * Medical contraindication to aspirin therapy * Molar pregnancy * Renal disease * Inability or unwillingness to give informed consent * Current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators
About the study
This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.
Sponsor: University of Tennessee Graduate School of Medicine · Participants: 50 · Started: Dec 10, 2025
Contact the study team
- Jill M Maples, PhD · Phone: 865-305-9367
- Hana O El-Messidi, BS · Phone: 865-305-5592
Official record on ClinicalTrials.gov — NCT07565727
Locations in the U.S.
| Tennessee | University of Tennessee Graduate School of Medicine, Knoxville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.